Antibacterial prophylaxis with levofloxacin in patients after allogeneic stem cell transplantation and neutrophil reconstitution: results from a double-blinded, placebo-controlled phase III trial and overview of recent clinical practice.
Martin
M
Schmidt-Hieber
Andrea
A
Stroux
Eckhard
E
Thiel
Igor Wolfgang
IW
Blau
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000382:microbiology / Q000628:therapy*; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000382:microbiology / Q000628:therapy*; D009504:Neutrophils / Q000166:cytology*; D015242:Ofloxacin / Q000627:therapeutic use*; D010919:Placebos; D033581:Stem Cell Transplantation / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D010919:Placebos; D064704:Levofloxacin; D015242:Ofloxacin